4月30日 - ** 医疗设备公司Senseonics SENS.O受潜在增资消息影响，盘后股价下跌12.3%至5.80美元
** 植入式连续血糖监测系统(CGM) 的制造商已启动 (link) 8000万美元的股票及预先融资认股权证发行
** 公司计划将募集资金净额用于持续推进Eversense 365系统的上市、继续开发其产品线及其他用途
** TD Cowen与巴克莱担任联合簿记管理人，瑞穗和Lake Street参与承销
** 这家总部位于马里兰州杰曼敦的公司目前流通股为4180万股，市值约为2.75亿美元
** 周四收盘上涨2.9%至6.61美元，年内累计涨幅扩大至20%
** 据伦敦证券交易所集团（LSEG）数据显示，覆盖该股的8位分析师中，5位给予“买入”评级，2位“持有”，1位“卖出”；目标价中位数为19.25美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.